Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Capital Employed (2016 - 2025)

CytomX Therapeutics' Return on Capital Employed history spans 11 years, with the latest figure at 0.03% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 60.0% year-over-year to 0.03%; the TTM value through Dec 2025 reached 0.03%, down 60.0%, while the annual FY2025 figure was 0.04%, 37.0% down from the prior year.
  • Return on Capital Employed reached 0.03% in Q4 2025 per CTMX's latest filing, down from 0.19% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.61% in Q1 2025 to a low of 1.11% in Q4 2022.
  • Average Return on Capital Employed over 5 years is 0.2%, with a median of 0.25% recorded in 2021.
  • Peak YoY movement for Return on Capital Employed: plummeted -73bps in 2022, then soared 100bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 0.42% in 2021, then tumbled by -166bps to 1.11% in 2022, then surged by 90bps to 0.12% in 2023, then surged by 587bps to 0.57% in 2024, then crashed by -106bps to 0.03% in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Return on Capital Employed are 0.03% (Q4 2025), 0.19% (Q3 2025), and 0.44% (Q2 2025).